Form 4: Bristol-Myers CFO Sells 56,000 Shares Under 10b5-1 Plan

Bristol-Myers Squibb's EVP and CFO, David V. Elkins, sold 56,000 shares of common stock for $47.33 per share, executed under a pre-arranged 10b5-1 trading plan.

Summary

• David V. Elkins, Executive Vice President and Chief Financial Officer of Bristol-Myers Squibb Co. (BMY), sold 56,000 shares of the company's common stock.
• The transaction occurred on September 2, 2025, at a weighted average price of $47.33 per share.
• The shares were sold in multiple transactions with prices ranging from $47.075 to $47.820.
• This sale was conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. Elkins on June 3, 2025.
• Following the transaction, Mr. Elkins directly beneficially owns 167,379 shares and indirectly owns 283.4 shares through the BMS Savings and Investment Program.

Sentiment

Score: 5

Explanation: The sale by the CFO is a neutral event given it was executed under a pre-arranged 10b5-1 plan, which mitigates the negative signal typically associated with insider selling. It reflects personal financial planning rather than a change in company outlook.

Positives

• The sale was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than a reaction to new, undisclosed negative information.

Negatives

• An insider sale, even if pre-planned, reduces the direct ownership stake of a key executive, which can sometimes be perceived as a slight reduction in alignment with shareholder interests.

Risks

• While mitigated by the 10b5-1 plan, significant insider selling could, in other contexts, signal a lack of confidence in the company's future performance.

Industry Context

Insider transactions, particularly by high-level executives like a CFO, are closely watched in the pharmaceutical industry as they can sometimes offer insights into management's perception of future company performance or liquidity needs. However, sales under a 10b5-1 plan are generally viewed as routine personal financial management rather than a signal about the company's prospects.

Stakeholder Impact

• Shareholders: The sale reduces the CFO's direct ownership, but the pre-planned nature under Rule 10b5-1 suggests it is for personal financial management rather than a reflection of company performance, thus minimizing negative impact on shareholder confidence.

Key Dates

Recommendation

The insider sale by the CFO is a routine transaction executed under a pre-arranged 10b5-1 plan, which is a common practice for executives to manage personal finances and diversify holdings. It does not provide new material information to warrant a change in investment thesis for Bristol-Myers Squibb. Investors should continue to hold based on the company's fundamentals and broader market conditions, rather than this specific insider transaction.

Keywords

Bristol-Myers Squibb, BMY, Insider Trading, Form 4, David V. Elkins, CFO, Stock Sale, 10b5-1 Plan, Pharmaceuticals, Biopharma